Substance / Medication

Dabigatran etexilate

Overview

Active Ingredient
dabigatran etexilate
RxNorm CUI
1037042

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
The risk of gastrointestinal bleeding in patients receiving dabigatran etexilate: a systematic review and meta-analysis of the literature.
Di Minno Matteo Nicola Dario, Ambrosino Pasquale, Di Minno Alessandro et al. · Ann Med · 2017
PMID: 28084107Meta-Analysis
Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review.
Marshall Sarah, Fearon Patricia, Dawson Jesse et al. · Expert Rev Pharmacoecon Outcomes Res · 2013
PMID: 23402443Meta-Analysis
Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery.
Wolowacz Sorrel E · Expert Rev Pharmacoecon Outcomes Res · 2011
PMID: 21351853Meta-Analysis
Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
Wolowacz Sorrel E, Roskell Neil S, Plumb Jonathan M et al. · Thromb Haemost · 2009
PMID: 19132192Meta-Analysis
A single-dose, four-cycle, fully repetitive crossover bioequivalence of dabigatran etexilate in Chinese.
Yang Zhuan, Li Qin, Yu Danfeng et al. · BMC Pharmacol Toxicol · 2025
PMID: 40087806RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Dabigatran etexilate (substance)
SNOMED CT
700029008
UMLS CUI
C1571583
RxNorm CUI
1037042

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.